Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabrafenib + trametinib + cetuximab + panitumumab + oxaliplatin + irinotecan + leucovorin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This is an **8-drug combination regimen** comprising the following agents:\n- **dabrafenib** (a BRAF inhibitor, small molecule),\n- **trametinib** (a MEK inhibitor, small molecule),\n- **cetuximab** and **panitumumab** (both EGFR-targeting monoclonal antibodies, usually used alternatively, not simultaneously, in regimens),\n- **oxaliplatin** and **irinotecan** (cytotoxic chemotherapies: platinum compound and topoisomerase I inhibitor, respectively),\n- **leucovorin** (folinic acid, biochemical modulator enhancing 5-fluorouracil activity),\n- **5-fluorouracil** (antimetabolite cytotoxic agent).\nThese drugs are used in combination primarily for the **treatment of metastatic colorectal cancer with BRAF mutations**, especially in the second-line setting. The combination targets multiple pathways associated with cancer cell growth and survival, including BRAF, MEK, EGFR, DNA replication, and is intended to overcome resistance mechanisms to single-agent targeted therapies. The combined use of these agents reflects a strategy to maximize antitumor activity through both targeted and cytotoxic approaches[1][2][3][4].
- Brand names
- Adrucil
- Other names
- dabrafenibtrametinibcetuximabpanitumumaboxaliplatinirinotecanleucovorin5-FU
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)DNAEGFR (Epidermal growth factor receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on dabrafenib + trametinib + cetuximab + panitumumab + oxaliplatin + irinotecan + leucovorin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabrafenib + trametinib + cetuximab + panitumumab + oxaliplatin + irinotecan + leucovorin + 5-fluorouracil.